Neuronetics, Inc. (NASDAQ: STIM) disclosed that Executive Vice President and Chief Financial Officer Steven Pfanstiel sold 16,431 shares of common stock on March 19, 2026. The sales generated approximately $22,017 and were completed at prices ranging from $1.20 to $1.48 per share.
According to a Form 4 filing with the Securities and Exchange Commission, the share disposals were carried out to satisfy tax obligations associated with the vesting of performance restricted stock units. After the transaction, Pfanstiel directly holds 828,781 shares of Neuronetics common stock.
Neuronetics is a medical device company with a market capitalization of $101 million. Its shares currently trade at $1.46, reflecting a near 69% decline over the past year, although the stock has shown short-term strength with an 18.8% gain over the last week.
Financial performance remains a challenge for the company. Over the most recent twelve-month period Neuronetics reported a loss per share of $0.59. Market research available through InvestingPro indicates the stock is trading close to its Fair Value, with subscribers receiving additional analytical material including six extra ProTips and a full Pro Research Report that covers STIM among more than 1,400 U.S. equities.
Recent company disclosures also detailed fourth-quarter 2025 results. Neuronetics posted revenue of $41.8 million, beating the forecast of $40.66 million and representing a 2.73% positive surprise. Earnings per share for the quarter were negative $0.10, underperforming the expected negative $0.09 and producing an 11.11% negative surprise.
Additional corporate developments include the appointment of Dan Reuvers as the company’s new chief executive officer. In coverage following the quarterly report, Canaccord lowered its price target to $3.00 from $7.00 but maintained a Buy rating, noting that the fourth-quarter results and guidance were consistent with expectations. The company also reported it was operationally cash flow positive in the second quarter.
These items - the insider sale to cover tax obligations, the mixed quarterly results, and the change in analyst valuation - provide investors with discrete data points as they assess Neuronetics’ near-term trajectory. The Form 4 filing makes clear the sale was tax-driven rather than a simple portfolio liquidation, while the operating and market metrics underline ongoing profitability and valuation questions for the medical device issuer.